| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2021 | AVANTYX, LLC | 1951 NW 7TH AVENUE | MIAMI | FL | 33136-1104 | MIAMI-DADE | USA | R41CA261451 | Analyzing the efficacy of MMP-13 inhibitors in the treatment of CIPN | 000 | 1 | NIH | 2/13/2024 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $355,723 ) |
| | 2021 | 2021 | AVANTYX PHARMACEUTICALS, LLC | 7901 SW 176TH ST | MIAMI | FL | 33157-6241 | MIAMI-DADE | USA | R41CA261451 | Analyzing the efficacy of MMP-13 inhibitors in the treatment of CIPN | 000 | 1 | NIH | 9/8/2021 | $350,664 |
| | 2021 | 2021 | AVANTYX PHARMACEUTICALS, LLC | 7901 SW 176TH ST | MIAMI | FL | 33157-6241 | MIAMI-DADE | USA | R41CA261451 | Analyzing the efficacy of MMP-13 inhibitors in the treatment of CIPN | 001 | 1 | NIH | 9/9/2021 | $5,059 |
|
|
